The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function
Abstract
MicroRNAs (miRNAs) are post-transcriptional gene expression regulators, playing key roles in neuronal development, plasticity and disease. Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the presence of protein inclusions or Lewy bodies and a progressive loss of dopaminergic neurons in the midbrain. Here, we have evaluated miRNA expression deregulation in PD brain samples. MiRNA expression profiling revealed decreased expression of miR-34b and miR-34c in brain areas with variable neuropathological affectation at clinical (motor) stages (Braak stages 4 and 5) of the disease, including the amygdala, frontal cortex, substantia nigra and cerebellum. Furthermore, misregulation of miR-34b/c was detected in pre-motor stages (stages 1-3) of the disease, and thus in cases that did not receive any PD-related treatment during life. Depletion of miR-34b or miR-34c in differentiated SH-SY5Y dopaminergic neuronal cells resulted in a moderate reduction in cell viability that was accompanied by altered mitochondrial function and dynamics, oxidative stress and reduction in total cellular adenosin triphosphate content. MiR-34b/c downregulation was coupled to a decrease in the expression of DJ1 and Parkin, two proteins associated to familial forms of PD that also have a role in idiopathic cases. Accordingly, DJ1 and Parkin expression was reduced in PD brain samples displaying strong miR-34b/c downregulation. We propose that early deregulation of miR-34b/c in PD triggers downstream transcriptome alterations underlying mitochondrial dysfunction and oxidative stress, which ultimately compromise cell viability. A better understanding of the cellular pathways controlling and/or controlled by miR-34b/c should allow identification of targets for development of therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“PD-related pathology was graded following Braak stages (3,4).”
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Small silencing RNAs: an expanding universe
Ghildiyal, M., & Zamore, P. D. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2504 · Cited by 2,325
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788
Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203
A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., Hannon, G., & Abeliovich, A. (2007) · Science · doi:10.1126/science.1140481 · Cited by 1,187
Cited by
ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age‐Related Diseases
Davalli, P., Mitic, T., Caporali, A., Lauriola, A., & D’Arca, D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3565127 · Cited by 1,059
Chin-Chan, M., Navarro-Yepes, J., & Quintanilla-Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 707
MicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 437
Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Bellingham, S. A., Guo, B. B., Coleman, B. M., & Hill, A. F. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00124 · Cited by 412
Exosomal miRNAs: Biological Properties and Therapeutic Potential
Hu, G., Drescher, K. M., & Chen, X.-M. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00056 · Cited by 394
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 364
The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila
Liu, N., Landreh, M., Cao, K., Abe, M., Hendriks, G.-J., Kennerdell, J. R., Zhu, Y., Wang, L.-S., & Bonini, N. M. (2012) · Nature · doi:10.1038/nature10810 · Cited by 356
The p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
Singh, S., & Singh, T. G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200207120949 · Cited by 291
Lekka, E., & Hall, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13182 · Cited by 251
Circulating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208
Wang, H., Ye, Y., Zhu, Z., Mo, L., Lin, C., Wang, Q., Wang, H., Gong, X., He, X., Lu, G., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12267 · Cited by 198
MicroRNAs and neurodegeneration: role and impact
Abe, M., & Bonini, N. M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.08.013 · Cited by 190
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
microRNA Profiles in Parkinson's Disease Prefrontal Cortex
Hoss, A. G., Labadorf, A., Beach, T. G., Latourelle, J. C., & Myers, R. H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00036 · Cited by 168
MicroRNAs in Neurodegenerative Diseases
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.04.002 · Cited by 168
Kim, J., Fiesel, F. C., Belmonte, K. C., Hudec, R., Wang, W.-X., Kim, C., Nelson, P. T., Springer, W., & Kim, J. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0121-4 · Cited by 172
“Recent miRNA profiling studies identified several miRNAs that are dysregulated in the affected regions of PD brains [35, 36, 62].”
BackgroundMarques, T. M., Kuiperij, H. B., Bruinsma, I. B., van Rumund, A., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0253-0 · Cited by 141
MicroRNA Expression and Regulation in Human, Chimpanzee, and Macaque Brains
Hu, H. Y., Guo, S., Xi, J., Yan, Z., Fu, N., Zhang, X., Menzel, C., Liang, H., Yang, H., Zhao, M., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002327 · Cited by 130
Kanagaraj, N., Beiping, H., Dheen, S. T., & Tay, S. S. W. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.039 · Cited by 130
Hébert, S. S., Wang, W.-X., Zhu, Q., & Nelson, P. T. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122350 · Cited by 125
Briggs, C. E., Wang, Y., Kong, B., Woo, T.-U. W., Iyer, L. K., & Sonntag, K. C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.05.021 · Cited by 113
Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease
Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108
Self-citationmicroRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
Lopez, J. P., Fiori, L. M., Gross, J. A., Labonte, B., Yerko, V., Mechawar, N., & Turecki, G. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000941 · Cited by 103
Li, N., Pan, X., Zhang, J., Ma, A., Yang, S., Ma, J., & Xie, A. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2841-9 · Cited by 97
Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus
Tatura, R., Kraus, T., Giese, A., Arzberger, T., Buchholz, M., Höglinger, G., & Müller, U. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.09.028 · Cited by 81
MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects
Cardo, L. F., Coto, E., Ribacoba, R., Menéndez, M., Moris, G., Suárez, E., & Alvarez, V. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0428-y · Cited by 75
Mamdani, M., Williamson, V., McMichael, G. O., Blevins, T., Aliev, F., Adkins, A., Hack, L., Bigdeli, T., D. van der Vaart, A., Web, B. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137671 · Cited by 73
Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis
Chen, Y., Wei, Q., Chen, X., Li, C., Cao, B., Ou, R., Hadano, S., & Shang, H.-F. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00069 · Cited by 69
Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration
Gascon, E., & Gao, F.-B. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00048 · Cited by 69
Involvement of MicroRNA in Microglia-Mediated Immune Response
Guedes, J., Cardoso, A. L. C., & Pedroso de Lima, M. C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/186872 · Cited by 65
The regulation of exosome function in the CNS: implications for neurodegeneration
Properzi, F., Ferroni, E., Poleggi, A., & Vinci, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14204 · Cited by 62
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer
Godlewski, J., Lenart, J., & Salinska, E. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010020 · Cited by 52
Yang, C. P., Zhang, Z. H., Zhang, L. H., & Rui, H. C. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0828-2 · Cited by 51
Therapeutic Role of Inflammasome Inhibitors in Neurodegenerative Disorders
Lahooti, B., Chhibber, T., Bagchi, S., Varahachalam, S. P., & Jayant, R. D. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.004 · Cited by 50
MiR-133b ameliorates axon degeneration induced by MPP+ via targeting RhoA
Niu, M., Xu, R., Wang, J., Hou, B., & Xie, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.042 · Cited by 49
Li, S., Bi, G., Han, S., & Huang, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.744942 · Cited by 45
Zhang, G., Chen, L., Liu, J., Jin, Y., Lin, Z., Du, S., Fu, Z., Chen, T., Qin, Y., Sui, F., et al. (2020) · Aging · doi:10.18632/aging.102636 · Cited by 44
MicroRNAs: Possible role in pathogenesis of Parkinson’s disease
Filatova, E. V., Alieva, A. K., Shadrina, M. I., & Slominsky, P. A. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912080020 · Cited by 39
Fu, Y., Zhen, J., & Lu, Z. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3643 · Cited by 39
Bortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Metadata
- Authors
- Miñones-Moyano, E., Porta, S., Escaramís, G., Rabionet, R., Iraola, S., Kagerbauer, B., Espinosa-Parrilla, Y., Ferrer, I., Estivill, X., & Martí, E.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-10
- Volume
- 20
- Issue
- 15
- Pages
- 3067-3078
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2165919884
- Cited by
- 482
- References
- 61
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.